CA2242481C - Method for liquid-liquid microextraction - Google Patents
Method for liquid-liquid microextraction Download PDFInfo
- Publication number
- CA2242481C CA2242481C CA002242481A CA2242481A CA2242481C CA 2242481 C CA2242481 C CA 2242481C CA 002242481 A CA002242481 A CA 002242481A CA 2242481 A CA2242481 A CA 2242481A CA 2242481 C CA2242481 C CA 2242481C
- Authority
- CA
- Canada
- Prior art keywords
- liquid
- solvent
- extraction method
- carrier
- micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 49
- 239000007788 liquid Substances 0.000 title claims description 31
- 238000004853 microextraction Methods 0.000 title claims description 25
- 239000002904 solvent Substances 0.000 claims abstract description 85
- 239000000126 substance Substances 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 239000000835 fiber Substances 0.000 claims description 33
- 239000012491 analyte Substances 0.000 claims description 19
- 239000012488 sample solution Substances 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000638 solvent extraction Methods 0.000 claims description 10
- 239000000123 paper Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000005373 porous glass Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 2
- 239000012510 hollow fiber Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 30
- 238000009835 boiling Methods 0.000 abstract description 15
- 229920002521 macromolecule Polymers 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 7
- 239000000969 carrier Substances 0.000 abstract description 5
- 239000012620 biological material Substances 0.000 abstract description 4
- 238000003795 desorption Methods 0.000 abstract description 4
- 239000011365 complex material Substances 0.000 abstract description 3
- 239000012141 concentrate Substances 0.000 abstract description 3
- 238000002470 solid-phase micro-extraction Methods 0.000 description 44
- 239000000523 sample Substances 0.000 description 34
- 239000003814 drug Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 20
- 229960003529 diazepam Drugs 0.000 description 12
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 238000000622 liquid--liquid extraction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229940049706 benzodiazepine Drugs 0.000 description 7
- 150000001557 benzodiazepines Chemical class 0.000 description 7
- 238000011953 bioanalysis Methods 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 238000013019 agitation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- -1 uncoated Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940127240 opiate Drugs 0.000 description 4
- 229940070721 polyacrylate Drugs 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000002594 sorbent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003965 capillary gas chromatography Methods 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000000881 depressing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- JJGYGPZNTOPXGV-UHFFFAOYSA-N 6-acetylmorphine Chemical compound C12C=CC(OC(C)=O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O JJGYGPZNTOPXGV-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960002808 pholcodine Drugs 0.000 description 1
- GPFAJKDEDBRFOS-FKQDBXSBSA-N pholcodine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCCN1CCOCC1 GPFAJKDEDBRFOS-FKQDBXSBSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
- G01N2001/4061—Solvent extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Abstract
A method of extraction and analysis of high boiling and/or macromolecular substances in complex materials, particularly biological material, comprising the following sequence of steps: (a) to provide a suitable carrier, (b) possibly to modify the carrier surface; (c) to immobilize a solvent on the surface of the carrier; (d) to contact the surface modified carrier with the material, possibly in the form of a solution, containing the substance to be analyzed; (e) to concentrate and fixate the substance to be analyzed in the solvent fixed on the carrier; and (f) to bring the carrier with the concentrated substance to be analyzed into an analytical apparatus for desorption and analysis.
As carriers there are preferably used fibres having a diameter of 50 to 300 µm, most preferably 100 to 200 µm, and of a length of about 2 cm.
As carriers there are preferably used fibres having a diameter of 50 to 300 µm, most preferably 100 to 200 µm, and of a length of about 2 cm.
Description
Method for Liquid-Liquid Microextraction ' The present invention relates to a method for liquid-liquid microextraction, more specifically, a method for the S extraction and analysis of high boiling and/or macromolecular substances in complex materials, particularly biological materials.
Sample preparation is the most tedious and time consuming step in analysis of drugs present in the pg/ml to y~g/ml concentration range in biological liquids such as blood, serum, plasma or urine. The principal steps of sample preparation involves concentration of the analytes and removal of as many interfering compounds as possible. The use of an extraction technique is common in the pre-treatment of most types of samples.
Liquid-liquid extraction or LLE is one of the most frequently used techniques. In liquid-liquid extraction the analyte is zo extracted from an aqueous matrix such as serum, plasma or urine into a water immiscible low boiling solvent. The type of matrix and the solvent are optimized to enable selective extraction of the analytes. The solvent is evaporated and the analytes reconstituted in a sufficiently small amount of solvent to obtain a concentrated solution for infection into an analytical instrument such as a gas chromatograph (GC) or a liquid chromatograph (HPLC). The advantage of LLE is the wide variety of solvents and solvent mixtures available to achieve a selective extraction of the analytes. However, LLE
3o have certain disadvantages, such as the time required, the relatively large sample volume required (a minimum of 0.5-1 ml), the use of a large volume of organic solvents which may be toxic, the formation of emulsions, and the need to con-centrate the extract by evaporation of solvent.
Solid Phase Extraction or SPE avoids or minimizes the dis-advantages of LLE listed above. The time required is reduced, the technique permits small sample volumes, it requires small volumes of solvents, and the formation of emulsions is avoided. If necessary, a low boiling solvent can be used in the final elution, and the solvent may be evaporated and the analytes reconstituted in a small volume of solvent before infection into an analytical instrument such as a GC or an HPLC.
SPE can easily be automated in off-line or on-line systems.
~ Certain of these carry out all the SPE process steps automatically, but the transfer of the eluates from SPE to a GC or an HPLC is manual. Others are able to transfer automatically the eluates to an HPLC injector to enable fully automated and unattended sample preparation and HPLC.
Fully automated on-line sample preparation and analysis was until recently only possible when the final separation method was HPLC. The ease of combining automated sample preparation with HPLC separation was one of the reasons why HPLC has ao developed into the mayor analytical separation method for drugs in biofluids. However, GC with capillary columns has a larger separation power than HPLC, and many specific and highly sensitive detectors are available. The development of new methods for sample preparation and infection techniques with a potential for on-line sample preparation and GC
analysis has been given a great deal of attention lately.
A promising experimental configuration recently introduced is the so-called solid phase microextraction or SPME, in which 3o the solid phase is a fibre of various materials such as uncoated, fused silica or optionally such silica coated with polydimethylsiloxane; polyimide; liquid crystal polyacry-late; Carbowag or graphite. These materials are all non-volatile and act as solid sorbents for partitioning of the analytes. For protection the fibre is mounted in the needle of a micro syringe. Upon sampling, the micro syringe plunger is depressed to lower the fibre in the liquid sample for a specific period of time. The analytes are adsorbed on the fibre aided by agitation of the sample. After adsorption of the analytes, the fibre is withdrawn into the needle. The analytes are then thermally desorbed by introducing the needle into the heated injection port of a gas chromatograph. The procedure can also be applied to the vapour phase in equilibrium with a liquid or solid to obtain head space sampling of volatiles. SPME can easily be automated by commercially available a~to-injectors for GC. SPME can also be used in combination with HPLC
as separation method.
With respect to the technology in this field, special reference shall be made to International Patent Application WO 9115745 in the name of Janusz B.
Pawliszyn, and to later literature by the same author.
SPME was developed for the analysis of organic compounds in water samples.
When SPME was applied to bioanalytical samples several difficulties were observed. The method showed insufficient enrichment in most cases. Drugs are high boiling compounds with a molecular weight of from 200 to 400 and are sorbed slowly onto the fibre. The enrichment will therefore take a long time and may require as much as 10 to 15 minutes. The biological sample solution has a high viscosity as compared with a water sample and the sorption of drugs onto the fibre is greatly reduced in a viscous sample. The selectivity was poor because the fibres for SPME are non-selective in nature. The consequence of a non-selective enrichment is many interfering compounds in the chromatograms. Biological macromolecules, such as proteins, are sorbed onto the fibre, and the fibre was rapidly contaminated.
The object of the present invention is to reduce the disadvantages of the SPME
technology and to provide a process that enhances the possibility of analyzing high boiling substances in complex samples, for example biological material and even environmental samples, and at the same time to increase the selectivity without renouncing the advantages of prior art.
Any suitable material may in principle be used as carrier, but the invention will be described with a fibre as carrier.
According to this, the present invention relates to a process of extraction and analysis of high boiling and/or macromole-cular substances in complex materials, particularly biological materials, and this process is characterized by the following sequence of steps:
(a) to provide a suitable carrier, (b) possibly to modify the carrier surface, (c) to immobilize a solvent on the surface of the carrier, (d) to contact the surface modified carrier with the material, possibly in the form of a solution, zo containing the substance to be analyzed, (e) to concentrate and fixate the substance to be analyzed, in the solvent fixed on the carrier, and (f) to bring the carrier with the concentrated substance to be analyzed into an ana lytical apparatus for z5 desorption and analysis.
Preferably a fibre is used as carrier.
The liquid-liquid microextraction, or LLME, of the invention 3o reduces or minimizes the problems encountered with SPME. The invention combines the advantages of LLE with the advantages of SPME. , In contrast to LLE, LLME is based on extraction onto an immobilized solvent. A carrier is used to immobilize the solvent. The amount of solvent which is immobilized is in the magnitude range of 2-5 girl. The carrier with the immobilized solvent is inserted into the sample solution.
The chemical properties of the biological matrix are altered, f for example by changing the pH, in order to favour partitio ning of the analytes into the~immobilized solvent. Upon 5 agitation the partitioning is generally complete within 2-6 minutes. The carrier with the enriched analytes dissolved in the immobilized solvent is then transferred to the infection port of an analytical instrument such as a GC which is maintained at a sufficient infection temperature. The immobilized solvent and the analytes evaporate and are separated on the GC column. No evaporation of solvent is necessary prior to infection. The total amount of solvent used for extraction is infected into the chromatograph and no solvent is wasted. In LLME only 1-5 p1 of solvent is used 5 for analysis, a circumstance which greatly reduces the risk of solvent exposure to operators and to the environment.
Solvents suitable for LLME can be divided into high boiling solvents and low boiling solvents. Solvents having a boiling aQ point in the range of 100 - 200°C are classified as high boiling solvents. These solvents evaporate slowly at room temperature and are well suited for LLME. These solvents have also powerful concentrating effect in splitless infection in capillary GC. A high starting temperature in 25 temperature programmed GC can be used, and a gain in analysis time is obtained. Examples of high boiling solvents for LLME are alcohols such as octanol, diols such as I.2-butanediol, ketones such as 22-octanone, ethers such as dibutylether, and esters such as pentylacetate. Low boiling 3o solvents such as those ordinarily used in LLE can also be used in LLME. These solvents can easily be evaporated from the carrier after enrichment, leaving high boiling analytes in a solvent free environment on the carrier. A solvent free infection can thereby be performed. Organic solvents have a 35 low viscosity as compared with the sorbents used in SPME.
High molecular weight substances such as drugs partition rapidly into the immobilized solvent as compared with the b high viscous SPME coating, resulting in short sorption time as compared with SPME. The selectivity can be optimized by varying of the chemical type of solvent and by mixing solvents. Macromolecules such as proteins are not soluble in organic solvents. This gives less contamination of the carrier, and the life time of the carrier is greatly extended as compared with the SPME fibre. LLME can in particular be used to analyze drugs Where the sample volume is less than 1 ml.
~o The requirements to be fulfilled by a carrier used in LLME is that it must provide the necessary surface area for immobi-lizing the solvent so as thereby to achieve rapid extraction of the analytes from the aqueous biofluid. In addition, it must be able to immobilize 1-5 u1 of solvent, be solvent re-sistant, be heat resistant up to 300oC and be pH insensitive, since it is generally used for extraction in the pH range of 2 to 12.
zo Many materials can act as carriers to immobilize solvents.
Examples of such materials are porous polymers; paper, porous glass, silica or metal; glass, silica or metal needles;
glass, silica or metal spirals or gauzes. The surface can be modified to enhance immobilization of organic solvents having hydrophobic bindings (Van der Waal's bindings) and deactivated to prevent strong interaction with analytes having polar bindings (dipole interaction and hydrogen bonding) or ionic interaction which may lead to reduced evaporation of the analyte from the carrier. In addition, so the carrier should be chemically inert to prevent catalytic degradation of the analytes during desorption in the heated GC injector.
Various devices can be used to bring the carrier into an , 35 analytical instrument, for example a GC. During the period from 1960 to 1980 a number of apparatuses were constructed for the introduction of solid samples into a GC. Some of these devices were based on modified syringes having a needle inside of a syringe needle. The advantage of the modified syringe design is that it can penetrate the septum of a GG
injector. Other devices were based on special holders which were screwed on the infection port of the GC. A carrier for a solid sample Was attached to a rod inside of the holder.
By a pressure on the rod, the carrier for the solid sample was inserted into the heated injector of the chromatograph, and the solid sample evaporated. In principle, both modified 7o syringes and modified infection devices for solid samples can be used for LLME. Modified syringes, like those used in SPME, offer the advantage that existing devices can be used also for LLME. However, instead of using a fibre coated with a SPME sorbent, a fibre for LLME is used.
zo LLME can also be used as a sampling technique for HPLC when corresponding injectors are used and when the HPLC mobile phase is compatible with the immobilized solvent used in LLME.
Analysis of a liquid sample through the metod of LLME and by means of a modified syringe involves the following steps:
First, the fibre is withdrawn into the needle of the syringe, z5 and the needle is used to penetrate septum of a solvent vial. The fibre is lowered into the solvent by depressing the plunger. The solvent is immobilized onto. the fibre and the plunger is withdrawn so that the fibre is withdrawn into the needle before the needle then is withdrawn from the so solvent vial.
Next, the needle is used to penetrate the sample vial, and the fibre is lowered into the sample by depressing the plunger. Analytes are partitioned onto the immobilized 35 solvent upon agitation of the sample vial. The plunger is then withdrawn so that the fibre is withdrawn into the needle before this is removed from the sample solution.
Sample preparation is the most tedious and time consuming step in analysis of drugs present in the pg/ml to y~g/ml concentration range in biological liquids such as blood, serum, plasma or urine. The principal steps of sample preparation involves concentration of the analytes and removal of as many interfering compounds as possible. The use of an extraction technique is common in the pre-treatment of most types of samples.
Liquid-liquid extraction or LLE is one of the most frequently used techniques. In liquid-liquid extraction the analyte is zo extracted from an aqueous matrix such as serum, plasma or urine into a water immiscible low boiling solvent. The type of matrix and the solvent are optimized to enable selective extraction of the analytes. The solvent is evaporated and the analytes reconstituted in a sufficiently small amount of solvent to obtain a concentrated solution for infection into an analytical instrument such as a gas chromatograph (GC) or a liquid chromatograph (HPLC). The advantage of LLE is the wide variety of solvents and solvent mixtures available to achieve a selective extraction of the analytes. However, LLE
3o have certain disadvantages, such as the time required, the relatively large sample volume required (a minimum of 0.5-1 ml), the use of a large volume of organic solvents which may be toxic, the formation of emulsions, and the need to con-centrate the extract by evaporation of solvent.
Solid Phase Extraction or SPE avoids or minimizes the dis-advantages of LLE listed above. The time required is reduced, the technique permits small sample volumes, it requires small volumes of solvents, and the formation of emulsions is avoided. If necessary, a low boiling solvent can be used in the final elution, and the solvent may be evaporated and the analytes reconstituted in a small volume of solvent before infection into an analytical instrument such as a GC or an HPLC.
SPE can easily be automated in off-line or on-line systems.
~ Certain of these carry out all the SPE process steps automatically, but the transfer of the eluates from SPE to a GC or an HPLC is manual. Others are able to transfer automatically the eluates to an HPLC injector to enable fully automated and unattended sample preparation and HPLC.
Fully automated on-line sample preparation and analysis was until recently only possible when the final separation method was HPLC. The ease of combining automated sample preparation with HPLC separation was one of the reasons why HPLC has ao developed into the mayor analytical separation method for drugs in biofluids. However, GC with capillary columns has a larger separation power than HPLC, and many specific and highly sensitive detectors are available. The development of new methods for sample preparation and infection techniques with a potential for on-line sample preparation and GC
analysis has been given a great deal of attention lately.
A promising experimental configuration recently introduced is the so-called solid phase microextraction or SPME, in which 3o the solid phase is a fibre of various materials such as uncoated, fused silica or optionally such silica coated with polydimethylsiloxane; polyimide; liquid crystal polyacry-late; Carbowag or graphite. These materials are all non-volatile and act as solid sorbents for partitioning of the analytes. For protection the fibre is mounted in the needle of a micro syringe. Upon sampling, the micro syringe plunger is depressed to lower the fibre in the liquid sample for a specific period of time. The analytes are adsorbed on the fibre aided by agitation of the sample. After adsorption of the analytes, the fibre is withdrawn into the needle. The analytes are then thermally desorbed by introducing the needle into the heated injection port of a gas chromatograph. The procedure can also be applied to the vapour phase in equilibrium with a liquid or solid to obtain head space sampling of volatiles. SPME can easily be automated by commercially available a~to-injectors for GC. SPME can also be used in combination with HPLC
as separation method.
With respect to the technology in this field, special reference shall be made to International Patent Application WO 9115745 in the name of Janusz B.
Pawliszyn, and to later literature by the same author.
SPME was developed for the analysis of organic compounds in water samples.
When SPME was applied to bioanalytical samples several difficulties were observed. The method showed insufficient enrichment in most cases. Drugs are high boiling compounds with a molecular weight of from 200 to 400 and are sorbed slowly onto the fibre. The enrichment will therefore take a long time and may require as much as 10 to 15 minutes. The biological sample solution has a high viscosity as compared with a water sample and the sorption of drugs onto the fibre is greatly reduced in a viscous sample. The selectivity was poor because the fibres for SPME are non-selective in nature. The consequence of a non-selective enrichment is many interfering compounds in the chromatograms. Biological macromolecules, such as proteins, are sorbed onto the fibre, and the fibre was rapidly contaminated.
The object of the present invention is to reduce the disadvantages of the SPME
technology and to provide a process that enhances the possibility of analyzing high boiling substances in complex samples, for example biological material and even environmental samples, and at the same time to increase the selectivity without renouncing the advantages of prior art.
Any suitable material may in principle be used as carrier, but the invention will be described with a fibre as carrier.
According to this, the present invention relates to a process of extraction and analysis of high boiling and/or macromole-cular substances in complex materials, particularly biological materials, and this process is characterized by the following sequence of steps:
(a) to provide a suitable carrier, (b) possibly to modify the carrier surface, (c) to immobilize a solvent on the surface of the carrier, (d) to contact the surface modified carrier with the material, possibly in the form of a solution, zo containing the substance to be analyzed, (e) to concentrate and fixate the substance to be analyzed, in the solvent fixed on the carrier, and (f) to bring the carrier with the concentrated substance to be analyzed into an ana lytical apparatus for z5 desorption and analysis.
Preferably a fibre is used as carrier.
The liquid-liquid microextraction, or LLME, of the invention 3o reduces or minimizes the problems encountered with SPME. The invention combines the advantages of LLE with the advantages of SPME. , In contrast to LLE, LLME is based on extraction onto an immobilized solvent. A carrier is used to immobilize the solvent. The amount of solvent which is immobilized is in the magnitude range of 2-5 girl. The carrier with the immobilized solvent is inserted into the sample solution.
The chemical properties of the biological matrix are altered, f for example by changing the pH, in order to favour partitio ning of the analytes into the~immobilized solvent. Upon 5 agitation the partitioning is generally complete within 2-6 minutes. The carrier with the enriched analytes dissolved in the immobilized solvent is then transferred to the infection port of an analytical instrument such as a GC which is maintained at a sufficient infection temperature. The immobilized solvent and the analytes evaporate and are separated on the GC column. No evaporation of solvent is necessary prior to infection. The total amount of solvent used for extraction is infected into the chromatograph and no solvent is wasted. In LLME only 1-5 p1 of solvent is used 5 for analysis, a circumstance which greatly reduces the risk of solvent exposure to operators and to the environment.
Solvents suitable for LLME can be divided into high boiling solvents and low boiling solvents. Solvents having a boiling aQ point in the range of 100 - 200°C are classified as high boiling solvents. These solvents evaporate slowly at room temperature and are well suited for LLME. These solvents have also powerful concentrating effect in splitless infection in capillary GC. A high starting temperature in 25 temperature programmed GC can be used, and a gain in analysis time is obtained. Examples of high boiling solvents for LLME are alcohols such as octanol, diols such as I.2-butanediol, ketones such as 22-octanone, ethers such as dibutylether, and esters such as pentylacetate. Low boiling 3o solvents such as those ordinarily used in LLE can also be used in LLME. These solvents can easily be evaporated from the carrier after enrichment, leaving high boiling analytes in a solvent free environment on the carrier. A solvent free infection can thereby be performed. Organic solvents have a 35 low viscosity as compared with the sorbents used in SPME.
High molecular weight substances such as drugs partition rapidly into the immobilized solvent as compared with the b high viscous SPME coating, resulting in short sorption time as compared with SPME. The selectivity can be optimized by varying of the chemical type of solvent and by mixing solvents. Macromolecules such as proteins are not soluble in organic solvents. This gives less contamination of the carrier, and the life time of the carrier is greatly extended as compared with the SPME fibre. LLME can in particular be used to analyze drugs Where the sample volume is less than 1 ml.
~o The requirements to be fulfilled by a carrier used in LLME is that it must provide the necessary surface area for immobi-lizing the solvent so as thereby to achieve rapid extraction of the analytes from the aqueous biofluid. In addition, it must be able to immobilize 1-5 u1 of solvent, be solvent re-sistant, be heat resistant up to 300oC and be pH insensitive, since it is generally used for extraction in the pH range of 2 to 12.
zo Many materials can act as carriers to immobilize solvents.
Examples of such materials are porous polymers; paper, porous glass, silica or metal; glass, silica or metal needles;
glass, silica or metal spirals or gauzes. The surface can be modified to enhance immobilization of organic solvents having hydrophobic bindings (Van der Waal's bindings) and deactivated to prevent strong interaction with analytes having polar bindings (dipole interaction and hydrogen bonding) or ionic interaction which may lead to reduced evaporation of the analyte from the carrier. In addition, so the carrier should be chemically inert to prevent catalytic degradation of the analytes during desorption in the heated GC injector.
Various devices can be used to bring the carrier into an , 35 analytical instrument, for example a GC. During the period from 1960 to 1980 a number of apparatuses were constructed for the introduction of solid samples into a GC. Some of these devices were based on modified syringes having a needle inside of a syringe needle. The advantage of the modified syringe design is that it can penetrate the septum of a GG
injector. Other devices were based on special holders which were screwed on the infection port of the GC. A carrier for a solid sample Was attached to a rod inside of the holder.
By a pressure on the rod, the carrier for the solid sample was inserted into the heated injector of the chromatograph, and the solid sample evaporated. In principle, both modified 7o syringes and modified infection devices for solid samples can be used for LLME. Modified syringes, like those used in SPME, offer the advantage that existing devices can be used also for LLME. However, instead of using a fibre coated with a SPME sorbent, a fibre for LLME is used.
zo LLME can also be used as a sampling technique for HPLC when corresponding injectors are used and when the HPLC mobile phase is compatible with the immobilized solvent used in LLME.
Analysis of a liquid sample through the metod of LLME and by means of a modified syringe involves the following steps:
First, the fibre is withdrawn into the needle of the syringe, z5 and the needle is used to penetrate septum of a solvent vial. The fibre is lowered into the solvent by depressing the plunger. The solvent is immobilized onto. the fibre and the plunger is withdrawn so that the fibre is withdrawn into the needle before the needle then is withdrawn from the so solvent vial.
Next, the needle is used to penetrate the sample vial, and the fibre is lowered into the sample by depressing the plunger. Analytes are partitioned onto the immobilized 35 solvent upon agitation of the sample vial. The plunger is then withdrawn so that the fibre is withdrawn into the needle before this is removed from the sample solution.
Finally, the solvent and the enriched analytes are evaporated in the in,~ector of a gas chromatograph followed by separation on the GC column. ' Most drugs used in human medicine are basic drugs, and analysis of basic drugs has been shown here in order to demonstrate the advantages of LLME in relation to SPME. In standard procedures these drugs are extracted from 0.5-1 ml of plasma by LLE or SPE. The extract is evaporated and the drugs are reconstituted in 50-100 yrl of solvent. 1-2 ~1 is infected into a GC for separation and analysis. The amount of drug infected into the chromatograph by this procedure is equivalent to the introduction of 10-20 y~l of plasma. In an equivalent enrichment based on LLME or SPME an amount of drug present in 10-20 1r1 of plasma will be quantitatively enriched on the fibre. If the enrichment is lower than in a standard procedure, microextraction will not provide the necessary enrichment for bioanalysis of drugs.
zo The invention will be further illustrated in the following examples with reference to the accompanying drawings where:
- Figure 1 illustrates the immobilization of solvent;
z5 - Figure 2 shows enrichment based on the use of SPME, respectively LLME;
- Figure 3 compares SPME with LLME in analysis of diazepam in human plasma;
- Figure 4A and 4B shows the chromatograms for a blank 3o plasma sample and a plasma sample having a different analyte;
- Figure 5A and 5B shows the chromatograms for a blank , plasma sample and plasma samples having different analytes; and 35 - Figure 6A and 6B shows the chromatograms for a blank plasma sample and a plasma sample having an additional analyte.
zo The invention will be further illustrated in the following examples with reference to the accompanying drawings where:
- Figure 1 illustrates the immobilization of solvent;
z5 - Figure 2 shows enrichment based on the use of SPME, respectively LLME;
- Figure 3 compares SPME with LLME in analysis of diazepam in human plasma;
- Figure 4A and 4B shows the chromatograms for a blank 3o plasma sample and a plasma sample having a different analyte;
- Figure 5A and 5B shows the chromatograms for a blank , plasma sample and plasma samples having different analytes; and 35 - Figure 6A and 6B shows the chromatograms for a blank plasma sample and a plasma sample having an additional analyte.
Preliminary experiments:
The principle of LLME can be demonstrated by the following experiment:
A cleaned filter paper having the dimensions of 1 mm x 5 mm was used as carrier for immobilization of 5 to 8 u1 of chloroform. The filter paper with immobilized chloroform is inserted into a 1 mmol/ml aqueous solution of diazepam at pH
5.5 and agitated for 1 minute. The solvent is partly evaporated before the filter paper is infected into the injector port of a GC with a solid injector screwed onto the infection port as described above. Analysis was carried out z5 on a packed GC column and an FID was used for detection. The experiment showed an enrichment factor for diazepam from the aqueous solution of 60 to 80.
Example 1 In this example the benzodiazepines diazepam and its metabolite N-desmethyldiazepam were determined in human plasma. Diazepam is highly bound to proteins in human plasma ( 98~ ) and in total drug analysis measures have to be taken to reduce the protein binding prior to the enrichment by LLME and SPME. For the analysis of the highly protein bound basic drugs in plasma, such as benzodiazepines, a general sample pretreatment procedure has been developed.
3~ To an amount of 450 u1 of plasma there was added 50 y~l methanol containing prazepam as internal standard. The mixture was agitated for 1 minute. The addition of methanol to plasma reduces the protein binding of the benzodiazepines.
,, Thereafter, plasma proteins were precipitated by addition of 100 u1 i M trichloroacetic acid solution. After centrifuga-tion at 13,000 rpm for 10 minutes, 100 y~l 5 M acetate buffer pH 7 was added to the 400 p1 supernatant, thus ensuring a final pH in the plasma supernatant of 5.5. Diazepam has its highest partition coefficient both into an immobilized organic solvent and into the SPME stationary phase at a pH
equal to 5.5. ' A polyacrylate SPME fibre was used as carrier for solvents in LLME. Both SPME analysis and LLME analysis of the plasma supernatant were carried out to demonstrate the differences between the two techniques. LLME was carried out with octanol as solvent. Octanol was immobilized on the SPME
fibre by inserting the fibre into an octanol solution for 2 minutes. The procedures for LLME and SPME with respect to plasma supernatant are identical. The fibres were inserted into the plasma supernatant. Partitioning onto the fibres was carried out by agitation of the sample vial for 4 minutes. The fibres were thereafter infected into the splitless injector of a capillary GC at 300°C. Desorption of the analytes was complete after 1 minute. The analytes were separated on a capillary column and detected by an NPD
zo detector.
The volume of immobilized solvent is an essential parameter in LLME and is dependant upon the type of solvent, the coating on the carrier, the surface area and the surface z5 tension on the carrier. The fibres designed for SPME were investigated as LLME carriers. The volume of solvent immobilized on various SPME fibres is shown in Figure 1. The polyacrylate coating was the best on the commercially available SPME fibres and was capable of immobilizing 1.5 yrl so of octanol and 3 u1 of 2-octanone. A number of high-boiling organic solvents were investigated, but all resulted in insufficient immobilization and/or incompatibility with the coating on the SPME fibres.
a The enrichment of diazepam in an aqueous acetate buffer pH
5.5 was determined by SPME and LLME for comparison of the two techniques. The enrichment factor was defined as the WO 97!25606 PCT/N09?/00010 equivalent volume in y~l of samples which were enriched, i.e., with an enrichment factor of 10 the amount of analyte in 10 p! of sample was concentrated on the coating or the immobili-zed solvent. By LLME with ~a polyacrylate coating an enrichment factor of about 90 was obtained with both octanol and 2-octanone as immobilized solvents. This clearly demonstrates the difference in selectivity between octanol and 2-octanone towards diazepam, since twice the amount of 2-octanone was required for enriching the same amount on the o SPME fibre. The enrichment obtained by SPME was about 40 as shown in Figure 2.
The enrichment of diazepam from plasma was less efficient since the biological sample contained several endogenous compounds and was highly viscous compared with the acetate buffer as shown in Figure 3. A decrease in partitioning was observed in both LLME and SPME. An enrichment factor of about 20 was obtained with LLME (octanol) while SPME for the same sample gave insufficient enrichment for bioanalysis of zo diazepam, with an enrichment factor of 6 with a sorption time of about 6 minutes.
The LLME procedure for the determination of diazepam in human plasma was validated and found to be reproducible. The z5 standard curves (calibration graphs) were found to be linear in the concentration range 0.25-7.5 nmol/ml with correlation coefficients of 0.9994 or better. The intro- and interassay validation of the procedure is shown in Table I. The limit of detection at a signal-to-noise ratio of 3 (S/Ng3) was 3o found to be 0.10 nmol/mo and in agreement with other pro-cedures for the determination of diazepam in human plasma.
Chromatograms from the LLME analysis of benzodiazepines are shown in figure 4.
Table I
W~ 97/25606 PCT/NC~97/00010 Intra- and interanalysis variations according to LLME, expressed as an average of parallel assays t standard deviation (S.D.) and relative standard deviation (R.S.D.). , r Added Concentration Measured Concentration R.S.D.
{nmol/ml) ~ S.D.
Intra-analysis (n=6) 0.50 0.48 f 0.02 4.2 3.00 2.92 t 0.17 5.8 56 5.00 4.96 ~ 0.16 3.2 56 Inter-analysis ~5 (n=6 ) 0. 50 0 . 48 f 0. 03 6 . 3 5d 3.00 2.94 ~ 0.19 6.5 56 5.00 4.98 ~ 0.28 5.6 56 2a Example 2 The potential of LLME in bioanalysis of drugs was investiga-ted by analysis of opiates, viz., codeine, ethyl morphine, morphine, 6-monoacetylmorphine and pholcodine and by the 25 analysis of a tricyclie antidepressant drug, viz., clozapine, all in human plasma. The plasma samples were pre-treated in the same manner as for the analysis of benzodiazepines:
addition of methanol and internal standard to ensure reduction of protein binding prior to protein precipitation.
3o LLME was carried out with octanol as solvent , and partitio-ning of the analytes into the solvent was carried out by agitation of the sample vial for 4 minutes. The immobilized octanol and the analyte were desorbed in the infection port (300°C) of a GC, and the separation was carried out with 35 ~-minor modifications of the temperature program used for the separation of the benzodiazepines and detected by NPD. The LLME analysis of the opiates as well as the analysis of the antidepressant were successful. The chromatograms from the LLME analysis of opiates and clozapine in human plasma are shown in Figures 5 and 6.
s LLME offers several advantages compared with SPME, viz:
- rapid sorption time - selectivity - high enrichment ~o - less contamination of the carrier/fibre - reduced adsorption of macromolecules.
LLME provides short sorption times compared with SPME as high molecular weight substances such as drugs partition rapidly into the immobilized solvent as compared with the high viscous SPME coating. The selectivity of LLME can be optimized for each specific application by variation of the chemical nature of the solvent and by mixing of solvents, while SPME is confined to the limited number of commercially zo available coatings. The number of organic solvents and mixtures of solvents available for LLME will always be greater than the number of coatings for SPME. The enrichment obtained by LLME was satisfactory for the bioanalysis of drugs and enables the analysis of human plasma samples even z5 though non-optimum SPME fibres were used as liquid carriers.
SPME did not provide sufficient enrichment for bioanalysis of most drugs. Macromolecules such as proteins are not soluble in organic solvents and this results in less contamination of the carrier and consequently increased life time, of the 3o carrier as compared with the SPME fibre. By optimizing LLME
the organic solvent will cover the carrier completely, and because macromolecules will not adsorb to the carrier, a pretreatment of samples with macromolecules, for example plasma, can be carried out without protein precipitation, 35 resulting in reduced sample preparation time and manual sample treatment.
The potential for LLME as a new technique for the determina-tion of drugs in bioanalysis and a supplementary technique to SPME has been demonstrated with non-optimum carriers.
Thus, LLME quite clearly offers sufficient enrichment for Y
bioanalysis of drugs, high selectivity and short sample preparation time. The applicability of the LLME technique of the invention has been shown for analysis of benzodiazepines, opiates and anti-depressants, but it is obvious that one does not depart from the spirit and framework of the invention if the technology of the invention should be used for other substances or if it should be based on other matrices.
The principle of LLME can be demonstrated by the following experiment:
A cleaned filter paper having the dimensions of 1 mm x 5 mm was used as carrier for immobilization of 5 to 8 u1 of chloroform. The filter paper with immobilized chloroform is inserted into a 1 mmol/ml aqueous solution of diazepam at pH
5.5 and agitated for 1 minute. The solvent is partly evaporated before the filter paper is infected into the injector port of a GC with a solid injector screwed onto the infection port as described above. Analysis was carried out z5 on a packed GC column and an FID was used for detection. The experiment showed an enrichment factor for diazepam from the aqueous solution of 60 to 80.
Example 1 In this example the benzodiazepines diazepam and its metabolite N-desmethyldiazepam were determined in human plasma. Diazepam is highly bound to proteins in human plasma ( 98~ ) and in total drug analysis measures have to be taken to reduce the protein binding prior to the enrichment by LLME and SPME. For the analysis of the highly protein bound basic drugs in plasma, such as benzodiazepines, a general sample pretreatment procedure has been developed.
3~ To an amount of 450 u1 of plasma there was added 50 y~l methanol containing prazepam as internal standard. The mixture was agitated for 1 minute. The addition of methanol to plasma reduces the protein binding of the benzodiazepines.
,, Thereafter, plasma proteins were precipitated by addition of 100 u1 i M trichloroacetic acid solution. After centrifuga-tion at 13,000 rpm for 10 minutes, 100 y~l 5 M acetate buffer pH 7 was added to the 400 p1 supernatant, thus ensuring a final pH in the plasma supernatant of 5.5. Diazepam has its highest partition coefficient both into an immobilized organic solvent and into the SPME stationary phase at a pH
equal to 5.5. ' A polyacrylate SPME fibre was used as carrier for solvents in LLME. Both SPME analysis and LLME analysis of the plasma supernatant were carried out to demonstrate the differences between the two techniques. LLME was carried out with octanol as solvent. Octanol was immobilized on the SPME
fibre by inserting the fibre into an octanol solution for 2 minutes. The procedures for LLME and SPME with respect to plasma supernatant are identical. The fibres were inserted into the plasma supernatant. Partitioning onto the fibres was carried out by agitation of the sample vial for 4 minutes. The fibres were thereafter infected into the splitless injector of a capillary GC at 300°C. Desorption of the analytes was complete after 1 minute. The analytes were separated on a capillary column and detected by an NPD
zo detector.
The volume of immobilized solvent is an essential parameter in LLME and is dependant upon the type of solvent, the coating on the carrier, the surface area and the surface z5 tension on the carrier. The fibres designed for SPME were investigated as LLME carriers. The volume of solvent immobilized on various SPME fibres is shown in Figure 1. The polyacrylate coating was the best on the commercially available SPME fibres and was capable of immobilizing 1.5 yrl so of octanol and 3 u1 of 2-octanone. A number of high-boiling organic solvents were investigated, but all resulted in insufficient immobilization and/or incompatibility with the coating on the SPME fibres.
a The enrichment of diazepam in an aqueous acetate buffer pH
5.5 was determined by SPME and LLME for comparison of the two techniques. The enrichment factor was defined as the WO 97!25606 PCT/N09?/00010 equivalent volume in y~l of samples which were enriched, i.e., with an enrichment factor of 10 the amount of analyte in 10 p! of sample was concentrated on the coating or the immobili-zed solvent. By LLME with ~a polyacrylate coating an enrichment factor of about 90 was obtained with both octanol and 2-octanone as immobilized solvents. This clearly demonstrates the difference in selectivity between octanol and 2-octanone towards diazepam, since twice the amount of 2-octanone was required for enriching the same amount on the o SPME fibre. The enrichment obtained by SPME was about 40 as shown in Figure 2.
The enrichment of diazepam from plasma was less efficient since the biological sample contained several endogenous compounds and was highly viscous compared with the acetate buffer as shown in Figure 3. A decrease in partitioning was observed in both LLME and SPME. An enrichment factor of about 20 was obtained with LLME (octanol) while SPME for the same sample gave insufficient enrichment for bioanalysis of zo diazepam, with an enrichment factor of 6 with a sorption time of about 6 minutes.
The LLME procedure for the determination of diazepam in human plasma was validated and found to be reproducible. The z5 standard curves (calibration graphs) were found to be linear in the concentration range 0.25-7.5 nmol/ml with correlation coefficients of 0.9994 or better. The intro- and interassay validation of the procedure is shown in Table I. The limit of detection at a signal-to-noise ratio of 3 (S/Ng3) was 3o found to be 0.10 nmol/mo and in agreement with other pro-cedures for the determination of diazepam in human plasma.
Chromatograms from the LLME analysis of benzodiazepines are shown in figure 4.
Table I
W~ 97/25606 PCT/NC~97/00010 Intra- and interanalysis variations according to LLME, expressed as an average of parallel assays t standard deviation (S.D.) and relative standard deviation (R.S.D.). , r Added Concentration Measured Concentration R.S.D.
{nmol/ml) ~ S.D.
Intra-analysis (n=6) 0.50 0.48 f 0.02 4.2 3.00 2.92 t 0.17 5.8 56 5.00 4.96 ~ 0.16 3.2 56 Inter-analysis ~5 (n=6 ) 0. 50 0 . 48 f 0. 03 6 . 3 5d 3.00 2.94 ~ 0.19 6.5 56 5.00 4.98 ~ 0.28 5.6 56 2a Example 2 The potential of LLME in bioanalysis of drugs was investiga-ted by analysis of opiates, viz., codeine, ethyl morphine, morphine, 6-monoacetylmorphine and pholcodine and by the 25 analysis of a tricyclie antidepressant drug, viz., clozapine, all in human plasma. The plasma samples were pre-treated in the same manner as for the analysis of benzodiazepines:
addition of methanol and internal standard to ensure reduction of protein binding prior to protein precipitation.
3o LLME was carried out with octanol as solvent , and partitio-ning of the analytes into the solvent was carried out by agitation of the sample vial for 4 minutes. The immobilized octanol and the analyte were desorbed in the infection port (300°C) of a GC, and the separation was carried out with 35 ~-minor modifications of the temperature program used for the separation of the benzodiazepines and detected by NPD. The LLME analysis of the opiates as well as the analysis of the antidepressant were successful. The chromatograms from the LLME analysis of opiates and clozapine in human plasma are shown in Figures 5 and 6.
s LLME offers several advantages compared with SPME, viz:
- rapid sorption time - selectivity - high enrichment ~o - less contamination of the carrier/fibre - reduced adsorption of macromolecules.
LLME provides short sorption times compared with SPME as high molecular weight substances such as drugs partition rapidly into the immobilized solvent as compared with the high viscous SPME coating. The selectivity of LLME can be optimized for each specific application by variation of the chemical nature of the solvent and by mixing of solvents, while SPME is confined to the limited number of commercially zo available coatings. The number of organic solvents and mixtures of solvents available for LLME will always be greater than the number of coatings for SPME. The enrichment obtained by LLME was satisfactory for the bioanalysis of drugs and enables the analysis of human plasma samples even z5 though non-optimum SPME fibres were used as liquid carriers.
SPME did not provide sufficient enrichment for bioanalysis of most drugs. Macromolecules such as proteins are not soluble in organic solvents and this results in less contamination of the carrier and consequently increased life time, of the 3o carrier as compared with the SPME fibre. By optimizing LLME
the organic solvent will cover the carrier completely, and because macromolecules will not adsorb to the carrier, a pretreatment of samples with macromolecules, for example plasma, can be carried out without protein precipitation, 35 resulting in reduced sample preparation time and manual sample treatment.
The potential for LLME as a new technique for the determina-tion of drugs in bioanalysis and a supplementary technique to SPME has been demonstrated with non-optimum carriers.
Thus, LLME quite clearly offers sufficient enrichment for Y
bioanalysis of drugs, high selectivity and short sample preparation time. The applicability of the LLME technique of the invention has been shown for analysis of benzodiazepines, opiates and anti-depressants, but it is obvious that one does not depart from the spirit and framework of the invention if the technology of the invention should be used for other substances or if it should be based on other matrices.
Claims (21)
1. A liquid-liquid micro-extraction method for extracting a target analyte from a sample solution, the method comprising steps of:
immobilizing a solvent on or ins a carrier to form an immobilized solvent;
inserting the carrier bearing the immobilized solvent into the sample solution;
extracting the target analyte into the immobilized solvent, thereby concentrating the target analyte; and analyzing the concentrated target analyte.
immobilizing a solvent on or ins a carrier to form an immobilized solvent;
inserting the carrier bearing the immobilized solvent into the sample solution;
extracting the target analyte into the immobilized solvent, thereby concentrating the target analyte; and analyzing the concentrated target analyte.
2. The liquid-liquid micro-extraction method of claim 1, wherein the target analyte comprises a plurality of analytes.
3. The liquid-liquid mica-extraction method of claim 1, wherein the carrier comprises a fiber.
4. The liquid-liquid micro-extraction method of claim 3, wherein the carrier comprises a hollow fiber.
5. The liquid-liquid micro-extraction method of claim 1, wherein the carrier comprises at least one of a porous polymer, paper, porous glass, silica and metal.
6. The liquid-liquid micro-extraction method of claim 3, wherein the fiber has a diameter of about 50 to 300 µm and a length of about 2 cm.
7. The liquid-liquid micro-extraction method of claim 3, wherein the fiber has a diameter of about 100 to 200 µm.
8. The liquid-liquid micro-extraction method of claim 1, further comprising a step of modifying the chemical properties of the sample solution to favor partitioning of the target analyte into the immobilized solvent.
9. ~The liquid-liquid micro-extraction method of claim 1, wherein the sample solution comprises a biological fluid.
10. ~The liquid-liquid micro-extraction method of claim 1, further comprising a step of adding an internal standard to the sample solution.
11. ~The liquid-liquid micro-extraction method of claim 1, further comprising a step of stirring the sample solution after the carrier bearing the immobilized solvent is inserted into the sample solution.
12. ~The liquid-liquid micro-extraction method of claim 1, wherein the step of immobilizing the solvent comprises immobilizing about 1 to 5 µl of solvent.
13. ~The liquid-liquid micro-extraction method of claim 1, wherein the step of analyzing the target analyte adhered to the immobilized solvent comprises inserting the carrier bearing the immobilized solvent and a captured target analyte into a gas chromatograph.
14. ~A liquid-liquid micro-extraction method for extracting a target analyte from a sample solution, the method comprising steps of:
placing a carrier into a syringe;
extending the carrier into a solvent to form an immobilized solvent;
withdrawing the carrier bearing the immobilized solvent;
extending the carrier bearing the immobilized solvent into the sample solution;
withdrawing the carrier bearing the immobilized solvent and a captured target analyte; and analyzing the target analyte by injecting the immobilized solvent and captured target analyte into a gas chromatograph injection port.
placing a carrier into a syringe;
extending the carrier into a solvent to form an immobilized solvent;
withdrawing the carrier bearing the immobilized solvent;
extending the carrier bearing the immobilized solvent into the sample solution;
withdrawing the carrier bearing the immobilized solvent and a captured target analyte; and analyzing the target analyte by injecting the immobilized solvent and captured target analyte into a gas chromatograph injection port.
15. ~The liquid-liquid micro-extraction method of claim 14, wherein the carrier comprises at least one of a porous polymer, paper, porous glass, silica and metal.
16. The liquid-liquid micro-extraction method of claim 14, wherein the carrier comprises a fiber.
17. The liquid-liquid micro-extraction method of claim 16, wherein the fiber has a diameter of about 50 to 300 µm and a length of about 2 cm.
18. The liquid-liquid micro-extraction method of claim 16, wherein the fiber has a diameter of about 100 to 200 µm.
19. The liquid-liquid micro-extraction method of claim 16, further comprising a step of modifying the chemical properties of the sample solution to favor partitioning of the target analyte into the immobilized solvent.
20. The liquid-liquid micro-extraction method of claim 16, wherein the sample solution comprises a biological fluid.
21. The liquid-liquid micro-extraction method of claim 16, further comprising a step of adding an internal standard to the sample solution.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO960133 | 1996-01-11 | ||
| NO960133A NO302056B1 (en) | 1996-01-11 | 1996-01-11 | Process for liquid-liquid microextraction |
| PCT/NO1997/000010 WO1997025606A1 (en) | 1996-01-11 | 1997-01-10 | Method for liquid-liquid microextraction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2242481A1 CA2242481A1 (en) | 1997-07-17 |
| CA2242481C true CA2242481C (en) | 2004-06-29 |
Family
ID=19898925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002242481A Expired - Fee Related CA2242481C (en) | 1996-01-11 | 1997-01-10 | Method for liquid-liquid microextraction |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0938654A1 (en) |
| AU (1) | AU714200B2 (en) |
| CA (1) | CA2242481C (en) |
| NO (1) | NO302056B1 (en) |
| WO (1) | WO1997025606A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19753701A1 (en) * | 1997-12-04 | 1999-06-17 | Fraunhofer Ges Forschung | Method and device for the quasi-continuous determination of inorganic or organic substances in fluids |
| AU2004200049B2 (en) * | 1998-12-01 | 2005-06-02 | Mette Krogh | Method and disposable devices for micro extraction |
| NO311464B1 (en) * | 1998-12-01 | 2001-11-26 | Pedersen Bjergaard Stig | Process and disposable micro-extraction device |
| JP2004529348A (en) * | 2001-04-26 | 2004-09-24 | エジーテック・アクチボラグ | Separation unit, separation method, and device for attaching separation unit to separation apparatus |
| US7178414B1 (en) * | 2004-02-27 | 2007-02-20 | Kokosa John M | Automation of liquid phase microextraction |
| CN102564836A (en) * | 2010-12-12 | 2012-07-11 | 复旦大学 | Method for analyzing residual organic solvents in bulk drug |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9007356D0 (en) * | 1990-04-02 | 1990-05-30 | Pawliszyn Janusz B | Micro solid phase extraction with fused silica optical fibres |
| US5576217A (en) * | 1995-02-28 | 1996-11-19 | Mallinckrodt Baker, Inc. | Solid phase microextraction of trace amounts of organic analytes |
-
1996
- 1996-01-11 NO NO960133A patent/NO302056B1/en not_active IP Right Cessation
-
1997
- 1997-01-10 CA CA002242481A patent/CA2242481C/en not_active Expired - Fee Related
- 1997-01-10 AU AU14576/97A patent/AU714200B2/en not_active Ceased
- 1997-01-10 WO PCT/NO1997/000010 patent/WO1997025606A1/en not_active Application Discontinuation
- 1997-01-10 EP EP97901276A patent/EP0938654A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU1457697A (en) | 1997-08-01 |
| CA2242481A1 (en) | 1997-07-17 |
| NO302056B1 (en) | 1998-01-12 |
| NO960133L (en) | 1997-07-14 |
| AU714200B2 (en) | 1999-12-23 |
| WO1997025606A1 (en) | 1997-07-17 |
| NO960133D0 (en) | 1996-01-11 |
| EP0938654A1 (en) | 1999-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pawliszyn et al. | Analytical microextraction: current status and future trends | |
| Kataoka | Recent advances in solid-phase microextraction and related techniques for pharmaceutical and biomedical analysis | |
| US8114660B2 (en) | Calibration procedures and devices for investigation biological systems | |
| US8080407B2 (en) | Calibration procedures and devices for investigation biological systems | |
| Kataoka | Recent developments and applications of microextraction techniques in drug analysis | |
| US8192692B2 (en) | Coated chromatograph injection port liner for performing surface sorbent | |
| AU2002327994B2 (en) | Method and apparatus for sample preparation using solid phase microextraction | |
| Hyötyläinen et al. | Sorbent-and liquid-phase microextraction techniques and membrane-assisted extraction in combination with gas chromatographic analysis: A review | |
| Barroso et al. | Role of microextraction sampling procedures in forensic toxicology | |
| US20050276727A1 (en) | Multiple sampling device and method for investigating biological systems | |
| Bagheri et al. | Sol–gel-based solid-phase microextraction and gas chromatography-mass spectrometry determination of dextromethorphan and dextrorphan in human plasma | |
| US20020009809A1 (en) | Disposable pipette extraction | |
| AU2002327994A1 (en) | Method and apparatus for sample preparation using solid phase microextraction | |
| Pawliszyn | Development of SPME devices and coatings | |
| US5827944A (en) | Sample screening and preparation within a collection vessel | |
| Gharari et al. | All‐in‐one solid‐phase microextraction: Development of a selective solid‐phase microextraction fiber assembly for the simultaneous and efficient extraction of analytes with different polarities | |
| CA2242481C (en) | Method for liquid-liquid microextraction | |
| AU766012B2 (en) | Method and disposable devices for micro extraction | |
| Kurečková et al. | Supercritical fluid extraction of steroids from biological samples and first experience with solid-phase microextraction–liquid chromatography | |
| CA2478970C (en) | Micro-devices and analytical procedures for investigation of biological systems | |
| Papadoyannis et al. | Sample pretreatment in clinical chemistry | |
| Kataoka et al. | SOLID-PHASE MICROEXTRACTION | |
| AU2004200049A1 (en) | Method and disposable devices for micro extraction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |